[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-access\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-access":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,68,89,114,146,170,205,231],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100642829","comparison-of-tunneled-cuffed-dialysis-catheters-versus-arteriovenous-fistulae-in-elderly-or-multimorbid-patients-100642829",false,"NCT07649083","Comparison of Tunneled Cuffed Dialysis Catheters Versus Arteriovenous Fistulae in Elderly or Multimorbid Patients","Inclusion Criteria:\n\n* Aged ≥60 years or \\\u003C60 years with a CCI Score \\>6\n* Patients with CKD G5 A1-3 with indication for hemodialysis\n* Stable clinical condition\n* Eligibility for both arteriovenous fistula on the upper extremities and TCC\n* Availability for follow-up\n* Written informed consent\n\nExclusion Criteria:\n\n* Uncontrolled infection and\u002For CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl) at screening\n* Poor overall health or malignancy not in remission at screening\n* Major surgery within 12 weeks before screening\n* Pre-existent vascular access\n* Patient not eligible for any one of the vascular access options\n* Endovascular arteriovenous fistula","ALL","18 Years","99 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients are randomly assigned to a study group. Depending on the study group, either an arteriovenous fistula or tunneled cuffed catheter (TCC) will be implanted, followed by continuous evaluation of the patients during the first year after initiating the vascular access. The evaluation includes statistical evaluation of all events, including loss of access, thrombosis, infection, loss of patency, increase in co-morbidities, e.g. congestive heart failure as well as quality of life. The implantation of the TCC is a standard procedure and it will be used only in accordance with the approved instructions of use on subjects who have signed an informed consent form. The surgery is a standard operation and it will be performed by specialized surgeons on subjects who have signed an informed consent form (No grafts will be used; implantation of a standard TCC, used at the Department of Nephrology). Both, an arteriovenous fistula or a TCC, will be used for routine chronic haemodialysis",[26,27,28,29,30],"End Stage Renal Failure, Hemodialysis","Vascular Access","Fistulas Arteriovenous","Haemodialysis Complication","Haemodialysis Patients","NOT_YET_RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":20},"2026-08-01",{"date":39,"type":20},"2030-12-31",{"name":41,"class":42},"Medical University of Vienna","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100641241","impact-of-a-tunneled-hemodialysis-catheter-with-endexo-technology-on-catheter-dysfunction-compared-with-historical-catheter-dysfunction-data-in-standard-catheters-100641241","NCT07655544","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters (Silicone or Polyurethane): A Pilot Study","Inclusion Criteria:\n\n* Adult patients aged greater than 18 years\n* Written informed consent\n* Requirement for hemodialysis using a tunneled dialysis catheter\n\nExclusion Criteria:\n\n* Children aged less than 18 years\n* Uncontrolled infection; defined as positive blood culture in the past seven days before catheter insertion and\u002F or elevated C-reactive protein \\[CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl)\\] at screening",{"count":51,"type":20},50,[23],"There is evidence that central venous catheters made of the permanent and non-eluting integral polymer Endexo® are more resistant to intraluminal thrombosis. This has a direct reducing effect on catheter malfunctions. Indirectly, due to reduced handling of the dysfunctional catheter, this may lead to a diminished rate of catheter related infections. Since catheter malfunctions and infections represent leading complications in a dialysis population, dialysis catheters produced with Endexo® technology have the potential to have beneficial clinical effects. In addition to improving patient outcomes, this could also reduce overall costs. In this pilot study the tunneled hemodialysis catheter BioFlo Duramax with Endexo® technology (Merit Medical, Utah, USA) will be compared with historical catheter dysfunction rates in standard tunneled dialysis catheters (silicone or polyurethane) in chronic dialysis population.",[55,29,27,56,57,58,59,60],"Haemodialysis","Vascular Access Complication","ESRD (End Stage Renal Disease)","Dialysis Access Dysfunction","Dialysis Catheter","Dialysis Catheter Infections",{"date":62,"type":35},"2026-06-18",{"date":37,"type":20},{"date":65,"type":20},"2027-12-31",{"name":41,"class":42},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100640370","early-feasibility-study-to-assess-the-safety-and-effectiveness-of-the-onepoint-dialysis-cannulatm-as-a-single-site-vascular-access-device-for-hemodialysis-procedures-100640370","NCT07599085","Early Feasibility Study to Assess the Safety and Effectiveness of the OnePoint Dialysis CannulaTM as a Single-Site Vascular Access Device for Hemodialysis Procedures","ONEPOINT-01","Inclusion Criteria:\n\n1. Subject is an adult patient ≥ 18 years of age.\n2. Subject with the ability to attend \"in-center\" hemodialysis.\n3. Subject has a requirement of hemodialysis 3 times\u002Fweek.\n4. Subject has an AVF that was determined to be mature by standard clinical definition\n5. Subject with ≥ 3 months stable in center hemodialysis with \\>90 days use of an AV fistula cannulated with 2 needles with no evidence of stenosis or thrombosis.\n6. Subject has an AVF that meets all of the following Rule of 5s:\n\n   * Flow ≥ 500 mL\u002Fmin\n   * Diameter ≥ 5 mm\n   * Depth ≤ 5 mm from the skin surface\n   * Length ≥ 5 cm usable for cannulation\n7. Subject does not have any established lesions or stents in the access circuit as confirmed by ultrasound.\n8. Subject dialyzes at a center that can confirm 30-day data collection on cannulations and is willing to cooperate in performing real-time assessments and record keeping per Sponsor requirements, to assure subject safety requirements.\n\nExclusion Criteria:\n\n1. Subject has an existing arteriovenous graft.\n2. Subject has any active infection within the past 90 days.\n3. Subject is currently receiving or planning home hemodialysis.\n4. Subject has a distorted anatomy and\u002For local vascular injury.\n5. Subject has a change in blood thinner regimen in the last 60 days.\n6. Subject has any unstable medical or psychiatric conditions likely to impair their ability to participate in the study.\n7. Subject has a known history of clinically significant IV drug use.\n8. Subject is a pregnant or nursing woman, or anticipates pregnancy in the next 3 months.\n9. Subject is enrolled in another study that could confound the results of this study, without documented pre-approval.\n10. Subject has a known allergy to plastics.\n11. Subject is unwilling to sign the study's consent form.\n12. Subject has a life expectancy of less than 12 months.",{"count":76,"type":20},20,[23],"This is an early feasibility, pre-market, prospective, interventional, single-arm, non-randomized \u002F open-label study intended to support a future pivotal IDE study for eventual FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.",[27],"2026-05-13",{"date":82,"type":35},"2026-05-20",{"date":37,"type":20},{"date":85,"type":20},"2027-08",{"name":87,"class":88},"Evolve Medicus, Inc.","INDUSTRY",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":15,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":67},"100608939","investigating-the-utility-of-augmented-reality-assistance-for-ultrasound-guided-vascular-access-100608939","NCT07208071","Investigating the Utility of Augmented Reality Assistance for Ultrasound-Guided Vascular Access","Application of Augmented Reality for Point of Care Ultrasound-Guided Procedures","Inclusion Criteria:\n\n* Patient requiring ultrasound-guided vascular access\n\nExclusion Criteria:\n\n* Age less than 5 years old\n* Need for urgent vascular access","5 Years",{"count":51,"type":20},[23],"This study will investigate the benefits of augmented reality assistance on ultrasound-guided vascular access. Using the Microsoft HoloLens 2 headset, the investigators will study the benefits of augmented reality technology as a tool for improving the success rate, efficiency, and ease of access for peripheral venous catheters, peripherally inserted central venous catheters, and central venous catheters.",[27],[102,103],"Augmented reality","ultrasound-guided vascular access","RECRUITING","2026-03-09",{"date":107,"type":35},"2026-03-10",{"date":109,"type":35},"2026-01-30",{"date":111,"type":20},"2026-07",{"name":113,"class":42},"University of Alabama at Birmingham",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":122,"targetDuration":124,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100622190","transulnar-access-in-patients-with-ipsilateral-radial-artery-occlusion-undergoing-coronary-angiography-or-angioplasty-100622190","NCT07380399","Transulnar Access in Patients With Ipsilateral Radial Artery Occlusion Undergoing Coronary Angiography or Angioplasty","Transulnar Access in Patients With Ipsilateral Radial Artery Occlusion Undergoing Coronary Angiography or Angioplasty: Safety and Effect on Hand Function (ULNART)","ULNART","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible:\n\n* Adults aged 18 years or older\n* Documented radial artery occlusion in the upper limb intended for vascular access, confirmed by ultrasound or angiography\n* Scheduled to undergo elective coronary angiography and\u002For angioplasty\n* Transulnar arterial access on the same side as the occluded radial artery is selected by the treating physician\n* Contralateral radial artery access is not feasible or is clinically undesirable, including for reasons such as:\n* documented occlusion or severe disease of the contralateral radial artery\n* unfavorable anatomy or prior failed access\n* strategic preservation of the contralateral radial artery for future surgical or dialysis needs\n* Adequate ulnar artery flow and anatomy for access, as assessed by pre-procedural ultrasound\n* Able and willing to provide written informed consent\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded:\n\n* Inadequate or absent ulnar artery flow at the intended access site on ultrasound\n* Known ulnar nerve injury or neuropathy affecting the access-side upper limb\n* Severe pre-existing motor or sensory dysfunction of the access-side hand that would interfere with functional assessment\n* Emergency coronary procedures that preclude baseline vascular or functional assessment\n* Participation in another interventional clinical study involving vascular access or intervention in the same upper limb\n* Local conditions at the intended access site, such as active infection, burn, or extensive scarring\n* Pregnancy or breastfeeding\n* Life expectancy less than 6 months",{"count":123,"type":20},127,"6 Months","OBSERVATIONAL","Coronary angiography and angioplasty are commonly performed through the radial artery at the wrist as this approach is associated with fewer bleeding complications and faster recovery. In some patients, the radial artery becomes occluded after prior procedures, requiring selection of an alternative access site for future coronary interventions.\n\nThe ulnar artery is a potential alternative wrist access. However, limited data are available on the safety of using the ulnar artery in the same arm as an occluded radial artery and on the possible effects on hand strength, sensation, and daily hand function.\n\nThe goal of this observational study is to evaluate the safety of transulnar access and its effect on hand function in adults with ipsilateral radial artery occlusion undergoing coronary angiography or angioplasty.\n\nThe main questions addressed by the study are:\n\n* How often do serious access-related vascular or nerve complications occur?\n* Does hand strength, sensation, or functional use of the hand change during follow-up?\n* Does the ulnar artery remain patent after the procedure? The choice of vascular access site is made by the treating physician based on clinical judgment. Participants who undergo transulnar access will undergo follow-up assessments, including ultrasound evaluation of arm arteries, standardized hand function testing, and short questionnaires assessing upper-limb function.\n\nThe findings of this study are expected to inform access-site selection, improve patient counseling, and support safer care for patients with radial artery occlusion undergoing coronary procedures.",[128,27,129],"Radial Artery Occlusion","Coronary Artery Disease (CAD)",[128,131,132,133,134,135],"Ulnar Artery","Coronary Angiography","Percutaneous Coronary Intervention","Upper Limb Function","Transulnar Access","2026-01-28",{"date":138,"type":35},"2026-02-02",{"date":140,"type":35},"2025-11-01",{"date":142,"type":20},"2032-01",{"name":144,"class":42},"National and Kapodistrian University of Athens",2,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":67},"100621546","single-needle-distal-return-for-long-term-arteriovenous-fistula-care-100621546","NCT07372027","Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care","A Prospective Study on the Efficacy and Cost-Effectiveness of Modified Single-Needle Distal Return Cannulation for Long-Term Arteriovenous Fistula Care in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years).\n\nDiagnosis of end-stage kidney disease (ESKD) requiring maintenance hemodialysis (three times per week).\n\nReliable use of a native arteriovenous fistula (AVF) as the primary vascular access for at least the past 3 months.\n\nWilling and able to provide written informed consent to participate in the study.\n\nAdequate superficial venous vasculature in at least one lower extremity (e.g., dorsal foot veins, saphenous tributaries) as assessed by clinical evaluation and\u002For bedside ultrasound, deemed suitable for cannulation as a venous return site.\n\nFor the experimental (SNDR) group: Expressed willingness to adopt the single-needle distal return cannulation strategy.\n\nFor the control group: Currently receiving and willing to continue standard two-needle AVF cannulation.\n\nExclusion Criteria:\n\n* Active systemic infection or localized infection at the potential cannulation sites (AVF or lower extremity veins).\n\nKnown severe coagulation disorder or thrombocytopenia (platelet count \\\u003C 50 × 10⁹\u002FL) that would pose a high risk of bleeding complications from cannulation.\n\nSevere peripheral arterial disease or venous insufficiency in the lower extremities that contraindicates venous cannulation or may compromise limb perfusion.\n\nUnstable cardiovascular status (e.g., uncontrolled heart failure, severe arrhythmias) as determined by the treating nephrologist, which would increase the risk associated with any change in dialysis procedure.\n\nDocumented severe cognitive impairment, psychiatric illness, or any condition that would impair the ability to provide informed consent or adhere to the study protocol.\n\nLife expectancy less than 12 months due to non-renal comorbid conditions (e.g., metastatic malignancy).\n\nCurrently pregnant or breastfeeding.\n\nParticipation in another interventional clinical trial that could confound the outcomes of this study.\n\nAnatomical or pathological condition of the AVF (e.g., extreme depth, aneurysm with overlying skin compromise, complete thrombosis) that precludes safe single-needle cannulation, as judged by the study vascular access team.\n\nInability to comply with the scheduled study visits and follow-up assessments.","100 Years",{"count":155,"type":20},100,[23],"Background:\n\nFor millions of people worldwide with kidney failure, a well-functioning vascular access, like an arteriovenous fistula (AVF), is essential for life-sustaining hemodialysis. However, the standard method requires puncturing the same AVF with two needles three times a week, which over time can damage the vessel, leading to scarring, narrowing, and frequent failures. These complications often require repeated surgical or minimally invasive procedures (reinterventions), causing significant pain, high medical costs, and exhaustion of the patient's limited blood vessels.\n\nNew Approach:\n\nThis study will evaluate a modified puncture technique called the Single-Needle Distal Return (SNDR) strategy for long-term AVF care. Instead of using two needles in the AVF, only one needle is placed in the AVF to draw blood. The cleaned blood is then returned to the body through a second needle placed in a superficial vein in the foot or lower leg. This approach aims to reduce trauma to the critical AVF.\n\nStudy Plan:\n\nThis is a clinical study conducted at the Blood Purification Center of Anhui Medical University Affiliated Suzhou Hospital. We plan to enroll approximately 50 adult hemodialysis patients who use an AVF and are willing to try the SNDR technique. For comparison, we will also observe data from a similar number of patients receiving standard two-needle AVF care during the same period.\n\nThe study will last about three years. We will closely monitor patients using the SNDR technique to assess:\n\nEffectiveness: Whether dialysis remains adequate (measured by Kt\u002FV).\n\nSafety: Rates of complications (like bruising or infection), dialysis machine alarms, and venous pressure during treatment.\n\nPractical Benefits: Whether it reduces the need for repair procedures (reinterventions) and hospitalizations related to the AVF.\n\nEconomic Impact: Changes in healthcare costs.\n\nPatient Experience: Patient tolerance and comfort with the technique. We will also analyze the characteristics of patients who successfully use this technique long-term to help identify who might benefit most from it in the future.\n\nPotential Significance:\n\nIf proven successful and safe for long-term use, the SNDR strategy could help protect a patient's precious AVF, potentially reducing painful procedures, lowering costs, slowing down the exhaustion of blood vessels, and improving the quality of life for people on long-term dialysis. The findings may also guide better planning for vascular access care.",[159,160,161,27,56],"Hemodialysis Access","Arteriovenous Fistula","Arteriovenous Fistula Cannulation","2026-01-19",{"date":136,"type":35},{"date":165,"type":20},"2026-12-15",{"date":167,"type":20},"2026-12-31",{"name":169,"class":42},"Suzhou Municipal Hospital of Anhui Province",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":181,"conditions":182,"keywords":188,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":4},"100588663","reduction-of-complications-associated-with-picc-management-100588663","NCT06944327","Reduction of Complications Associated With PICC Management","Reduction of Complications Associated With PICC Management. Randomization in Care.","PICC managemen","Inclusion Criteria:\n\n* be over 18 years of age\n* accept participation in the study\n* independent patient in the care and management of activities of daily living\n\nExclusion Criteria:\n\n* patient over 18 years of age\n* patient with functional or cognitive limitation\n* patient with mild, moderate or high level of dependence\n* patient does not accept to perform the study\n* patient with device withdrawal prior to 14 days of duration",{"count":179,"type":20},460,[23],"The present study aims to analyze different care routes of the peripheral access central venous catheter to assess which alternative allows a moderate reduction in the level of complications associated with prolonged care frequency, due to the reduction of device manipulation.\n\nA high level of patient satisfaction is detected due to the controlled follow-up of the device care, as well as a decrease in the need for transfer to a center for follow-up.\n\nObjective: Identify the type of care frequency for PIVCs most beneficial for the reduction of complications associated with extraluminal device care (thrombosis, phlebitis, accidental removal, obstruction).",[183,27,184,56,185,186,187],"Treatment Outcome","Vascular Access Device","Care Delivery","Nurse","Nurse Based Care Management",[189,190,191,192,193,194,195,196],"vascular","vascular access","catheter","central catheter","nurse","vascular access device","management","complication","2025-04-23",{"date":199,"type":35},"2025-04-25",{"date":201,"type":20},"2025-10-01",{"date":65,"type":20},{"name":204,"class":42},"Fundacion Miguel Servet",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":213,"targetDuration":215,"studyType":125,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":67},"100588504","vascular-access-registry-100588504","NCT06942260","Vascular Access Registry","Vascular Access Registry (VARegistry) - Prospective Registry of Vascular Access","VARegistry","Inclusion Criteria:\n\n* Indication for percutaneous cardiac procedure\n\nExclusion Criteria:\n\n* No exclusion criteria exist",{"count":214,"type":20},1157,"30 Days","The Vascular Access Registry (VARegistry) is a prospective patient registry that will be conducted at the Hemodynamic Laboratory of the Cardiology Clinic of the University General Hospital of Patras.\n\nThe puncture of the vessel will be performed either using palpation, anatomical landmarks or using ultrasound guidance, depending on the ability and preference of each operator. Patients who meet all admission criteria and no exclusion criteria will be admitted to the study.\n\nPatients \\>18 years of age presented with indication for any percutaneous cardiac procedure will be included in the study. No exclusion criteria exist.\n\nThe vascular puncture will be performed according to current guidelines and on the basis of recent scientific data. If the attempt to obtain access from the selected location is unsuccessful, the access location will be changed. The choice of the new access location in case of failure of the originally selected one is subject to the preference of each operator.\n\nParticipants will be monitored for the period they remain hospitalized, depending on the initial indication of intervention, and a follow-up with a vascular ultrasound after one month is recommended.\n\nThe primary endpoint is the percentage of success of the puncture at the initial access point.\n\nThe secondary endpoints are as follows:\n\n* Percentages of successful puncture of vascular access with and without the use of ultrasound guidance\n* Occlusion rate of the access artery before discharge\n* Crossover rate of access site during procedure\n* Time to sheath placement during procedure\n* Total intervention time\n* Procedure duration (from the sheath insertion to the completeness of the procedure)\n* Total fluoroscopy time\n* Total DAP (Dose area product)\n* Air Kerma\n* Time required for hemostasis\n* Vascular complications \\*\n* Classification of hematomas (modified classification by EASY)\\*\\*\n* Vascular implication of access artery using ultrasound monitoring of patients at 30 days\n\n  * VARC criteria \\*\\* if the forearm has been used",[27,218],"Coronary Interventions",[27,218,132,220,221],"Radial Artery","Distal Radial Artery","2025-04-16",{"date":224,"type":35},"2025-04-24",{"date":226,"type":35},"2025-01-01",{"date":228,"type":20},"2026-06-30",{"name":230,"class":42},"University Hospital of Patras",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":15,"minAge":239,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":250,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":67},"100588234","novel-medical-device-for-pharmacological-therapy-100588234","NCT06938750","Novel Medical Device for Pharmacological Therapy","A Pilot Study of a Novel Medical Device for Pharmacological Therapy: The SecHold Device","Sechold","Inclusion Criteria:\n\n* patients admitted to the intensive care unit\n* patients with authorization to take part in the study\n\nExclusion Criteria:\n\n* Patients with pre-existing medical conditions: Patients with diseases affecting coagulation, such as hemophilia or thrombocytopathies, could be excluded.\n* Active infection patients: Any patient with vascular access site infections or systemic infections may be excluded to avoid complications.\n* Inability to give informed consent: Patients who are unable to understand or consent to participate in the study.","1 Year",{"count":241,"type":20},262,[23],"Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.",[27,56,245,246,247,248,186,187,249],"Vascular Access Complications","Catheter Malfunction","Catheter Infection","Therapeutic Drug Management","Innovative Procedures",[251,252,253,254,255,256],"VASCULAR ACCESS","CATHETER","THERAPY","COMPLICATION","DEVICE","CENTRAL VASCULAR ACCESS","2025-04-14",{"date":259,"type":35},"2025-04-22",{"date":261,"type":35},"2023-01-20",{"date":263,"type":20},"2026-09-20",{"name":204,"class":42}]